Morgan Stanley upgrades Croda stock rating on pricing power outlook By Investing.com

Morgan Stanley upgraded Croda International to Overweight and raised its price target to GBP33.50 (from GBP32.80). The bank cites Croda’s faster pass-through of input inflation (~1-quarter lag vs peers ~2 quarters), GBP35m gross savings in fiscal 2026, and limited downside to 2026 adjusted EPS; company metrics include a $5.1bn market cap, P/E of 61.7, 3.8% dividend yield and 43.9% gross margin. Morgan Stanley forecasts 2026 like-for-like and adjusted EPS growth of 3.8% and 7.2% vs peers at 2.2% and 6.4%, and notes inventory of ~2.6 months supporting quicker pass-through.

Analysis

Croda’s structural advantage is less about a one-off cost save and more about the mechanics of working capital and customer economics: faster pass‑through shortens real cash conversion cycles and effectively converts temporary commodity shocks into recurring margin tailwinds. That dynamic will amplify returns on any fixed-cost deleveraging (R&D, plant automation) because incremental margin sits on a smaller capital base, creating non-linear EPS upside over 2–4 quarters if end-market volumes are stable.

The second‑order winners are specialty formulators and contract manufacturers that source from a supplier with predictable pricing cadence — they can model input inflation with shorter horizons and reduce hedging costs. Losers include commodity raw‑material merchants and ingredient rivals that must carry longer inventory lags or concede price concessions; over time that could trigger consolidation among mid‑tier players and increase buyer concentration risk for blue‑chip CPGs.

Key upside catalysts are repeatable delivery of leading pass‑through metrics across two consecutive quarters and confirmation that savings initiatives convert to operating leverage; downside reversals would come quickly from either durable end‑market weakness, an unexpected collapse in raw material costs (removing pricing justification), or customer pushback on pass‑through during FMCG margin resets. The market has likely priced a continuation of execution — if that falters the premium multiple is the lever that unwinds fastest over 3–12 months.

Key Decisions for Investors

• Long CRDA (LON:CRDA) 6–12 month equity position sized 2–3% of NAV; target 20–30% upside if two sequential quarters confirm faster pass‑through and margin accretion. Use a hard stop of 10% to limit downside if guidance softens or raw‑material indices drop sharply.
• Pair trade: long CRDA / short IFF (NYSE:IFF) equal notional for a 3–9 month trade to isolate company execution vs sector cyclicality. Expect 15–25% relative outperformance if Croda sustains faster pricing mechanics; tighten or unwind if the CRDA–IFF spread compresses >8% in 30 days.
• Buy a 9–12 month CRDA call spread (debit call spread) to capture re‑rating with defined downside — size to risk no more than 0.5–1% of NAV. Hedge by selling 1–3 month calls against 25% of the notional to monetize near‑term premium if volatility spikes around results.
• Event hedge: purchase short‑dated puts on CRDA ahead of next quarterly report (4–6 weeks) sized small (0.25–0.5% NAV) to protect against an execution miss or customer pushback shock; unwind promptly if results meet or beat consensus.